ArticleJournal of pain research2015
Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease.
Article in Journal of pain research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Multidimensional Treatment of Cancer Pain.Current oncology reports · 2017Pooled it
- Efficacy of oral tapentadol immediate-release for the management of moderate-to-severe cancer pain in patients presenting to the oncology ward of a tertiary care hospital.Pakistan journal of medical sciences · 2026Article
- Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease.Cancer pathogenesis and therapy · 2025Article
- Differences in the Analgesic Effect of Opioids on Pain in Cancer Patients With Spinal Metastases.Palliative medicine reports · 2023Article
- Tapentadol: A Review of Experimental Pharmacology Studies, Clinical Trials, and Recent Findings.Drug design, development and therapy · 2023Review
- Neurophysiological Mechanisms Related to Pain Management in Bone Tumors.Current neuropharmacology · 2021Article
- Review
- Review
- Tapentadol for neuropathic pain: a review of clinical studies.Journal of pain research · 2019Review
- Tapentadol in the management of cancer pain: current evidence and future perspectives.Journal of pain research · 2019Review
- Tapentadol in neuropathic pain cancer patients: a prospective open label study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Article
- Tapentadol extended release for the management of chronic neck pain.Journal of pain research · 2017Article
- Bone pain mechanism in osteoporosis: a narrative review.Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal DiseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextMyeloma bone disease (MBD) is a devastating complication of multiple myeloma that leads to severe pain.
objectivesThe aim of this study was to evaluate the efficacy and tolerability of tapentadol prolonged release (PR) in the management of patients with MBD suffering from moderate-to-severe cancer pain.
methodsA 12-week prospective study was carried out in 25 opioid-naïve MBD patients. Patients initially received twice-daily doses of tapentadol PR 50 mg. Doses were then managed to maintain adequate relief or dose-limiting toxicity. The following parameters were recorded at weekly intervals for 4 weeks, and then at weeks 8 and 12: pain, opioid-related adverse effects, use of other analgesics, DN4 (Douleur Neuropathique 4) score. Quality of life (SF-36 [36-item short-form health survey]) was measured at baseline and at final evaluation.
resultsOf 25 patients, 22 completed the study. Pain intensity significantly decreased from baseline to all the week intervals (P<0.01). Quality of life significantly improved with respect to all SF-36 subscale parameters (P<0.01), and so did both the physical and mental status (P<0.01). Tapentadol PR significantly reduced DN4 mean value (P<0.01) and the number of patients with neuropathic component (DN4 ≥4) (P<0.01). After 8 weeks of treatment, all patients were negative for the DN4 score. Tapentadol PR was well tolerated, and the use of other analgesics was reduced during the study period.
conclusionTapentadol PR started in doses of 100 mg/day was effective and well tolerated in opioid-naïve MBD patients with moderate-to-severe pain. Tapentadol PR can be considered a first-choice opioid in cancer patients suffering from mixed pain with a neuropathic component.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.